Literature DB >> 25332979

Circulating free DNA in the management of breast cancer.

Jacqueline A Shaw1, Justin Stebbing1.   

Abstract

Circulating cell-free DNA (cfDNA) is now under investigation as a "liquid biopsy" in the real time management of cancer. In The New England Journal of Medicine Dawson et al. reported a proof of concept investigation of tumour specific alterations in cfDNA and demonstrate that this fraction termed "circulating tumour DNA" (ctDNA) shows greater correlation with changes in tumour burden than two other circulating biomarkers (CA 15-3 and circulating tumor cell counts) in individuals with metastatic breast cancer receiving therapy.

Entities:  

Keywords:  Breast cancer; biomarkers; circulating tumour DNA; circulating tumour cells (CTCs)

Year:  2014        PMID： 25332979      PMCID： PMC4200656          DOI： 10.3978/j.issn.2305-5839.2013.06.06

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  18 in total

1.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Authors:  Sandra Misale; Rona Yaeger; Sebastijan Hobor; Elisa Scala; Manickam Janakiraman; David Liska; Emanuele Valtorta; Roberta Schiavo; Michela Buscarino; Giulia Siravegna; Katia Bencardino; Andrea Cercek; Chin-Tung Chen; Silvio Veronese; Carlo Zanon; Andrea Sartore-Bianchi; Marcello Gambacorta; Margherita Gallicchio; Efsevia Vakiani; Valentina Boscaro; Enzo Medico; Martin Weiser; Salvatore Siena; Federica Di Nicolantonio; David Solit; Alberto Bardelli
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

Review 2.  Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.

Authors:  Emmanuelle Gormally; Elodie Caboux; Paolo Vineis; Pierre Hainaut
Journal:  Mutat Res       Date:  2007-01-25       Impact factor: 2.433

3.  [Not Available].

Authors:  P MANDEL; P METAIS
Journal:  C R Seances Soc Biol Fil       Date:  1948-02

Review 4.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

Review 5.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Authors:  Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

6.  Analysis of circulating tumor DNA to monitor metastatic breast cancer.

Authors:  Sarah-Jane Dawson; Dana W Y Tsui; Muhammed Murtaza; Heather Biggs; Oscar M Rueda; Suet-Feung Chin; Mark J Dunning; Davina Gale; Tim Forshew; Betania Mahler-Araujo; Sabrina Rajan; Sean Humphray; Jennifer Becq; David Halsall; Matthew Wallis; David Bentley; Carlos Caldas; Nitzan Rosenfeld
Journal:  N Engl J Med       Date:  2013-03-13       Impact factor: 91.245

7.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

8.  Detection of HER2 amplification in circulating free DNA in patients with breast cancer.

Authors:  K Page; N Hava; B Ward; J Brown; D S Guttery; C Ruangpratheep; K Blighe; A Sharma; R A Walker; R C Coombes; J A Shaw
Journal:  Br J Cancer       Date:  2011-03-22       Impact factor: 7.640

9.  Circulating tumour markers can define patients with normal colons, benign polyps, and cancers.

Authors:  R Mead; M Duku; P Bhandari; I A Cree
Journal:  Br J Cancer       Date:  2011-06-28       Impact factor: 7.640

10.  LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.

Authors:  Jan Dominik Kuhlmann; Heidi Schwarzenbach; Pauline Wimberger; Micaela Poetsch; Rainer Kimmig; Sabine Kasimir-Bauer
Journal:  BMC Cancer       Date:  2012-07-31       Impact factor: 4.430
View more
  11 in total

Review 1.  Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker.

Authors:  Mersedeh Rohanizadegan
Journal:  Cancer Genet       Date:  2018-02-24

Review 2.  Liquid Biopsies for Cancer: Coming to a Patient near You.

Authors:  Nithya Krishnamurthy; Emily Spencer; Ali Torkamani; Laura Nicholson
Journal:  J Clin Med       Date:  2017-01-04       Impact factor: 4.241

Review 3.  The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor.

Authors:  Yating Chen; Wenjie Guo; Junsheng Fan; Yuqing Chen; Xiaoli Zhang; Xin Chen; Peng Luo
Journal:  Cancer Manag Res       Date:  2017-12-07       Impact factor: 3.989

4.  TIPE3 protein promotes breast cancer metastasis through activating AKT and NF-κB signaling pathways.

Authors:  Kaili Lian; Chao Ma; Chunyan Hao; Yan Li; Na Zhang; Youhai H Chen; Suxia Liu
Journal:  Oncotarget       Date:  2017-07-25

5.  Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.

Authors:  Yu-Hsiang Chen; Bradley A Hancock; Jeffrey P Solzak; Dumitru Brinza; Charles Scafe; Kathy D Miller; Milan Radovich
Journal:  NPJ Breast Cancer       Date:  2017-07-03

6.  Rapid Changes in Circulating Tumor DNA in Serially Sampled Plasma During Treatment of Breast Cancer: A Case Report.

Authors:  Hiroshi Nakagomi; Yosuke Hirotsu; Kenji Amemiya; Haruka Nakada; Masayuki Inoue; Hitoshi Mochizuki; Toshio Oyama; Masao Omata
Journal:  Am J Case Rep       Date:  2017-01-09

Review 7.  Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer.

Authors:  Ivana Bratić Hench; Jürgen Hench; Markus Tolnay
Journal:  Front Med (Lausanne)       Date:  2018-01-30

8.  HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.

Authors:  Hitomi Sakai; Junji Tsurutani; Tsutomu Iwasa; Yoshifumi Komoike; Kazuko Sakai; Kazuto Nishio; Kazuhiko Nakagawa
Journal:  Breast Cancer       Date:  2018-04-26       Impact factor: 4.239

9.  The number of tumorspheres cultured from peripheral blood is a predictor for presence of metastasis in patients with breast cancer.

Authors:  Monika Pizon; Dorothea Schott; Ulrich Pachmann; Katharina Pachmann
Journal:  Oncotarget       Date:  2016-07-26

Review 10.  [Advances in Liquid Biopsy and its Clinical Application in the Diagnosis 
and Treatment of Non-small Cell Lung Cancer].

Authors:  Difan Zheng; Haiquan Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.